-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Safety & Regulatory Compliance
-
Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Global Public Health
- Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell and Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases and Vaccines
- Oncology
- Pediatrics
- Rare Diseases
- View All
Impacting People's Lives
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWSafety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
BLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
FEATURED INNOVATIONS
-
IQVIA Connected Intelligence™
-
IQVIA Healthcare-grade AI™
-
IQVIA AI Assistant
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Patient Experience Solutions with Apple devices
WHO WE ARE
- Our Story
- Our Impact
- Commitment to Public Health
- Code of Conduct
- Environmental Social Governance
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
IQVIA AI is Healthcare-grade AI
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Meet the IQVIA AI Assistant
Your new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
IQVIA Patient Experience Solutions with Apple devices
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREWORKING AT IQVIA
Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORELIFE AT IQVIA
Careers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE
WE’RE HIRING
"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSBlog
Biosimilars to continue rapid growth over the next decade
Jan 03, 2022
Globally, the uptake of parenteral biosimilars is increasing rapidly and this trend looks set to continue over the next decade. According to IQVIA’s Forecast Link, biosimilar value grew at a CAGR of 78% between 2015 and 2020, reaching approximately $17.9 bn in 2020 and is expected to continue growing at a CAGR of 15% between 2020 and 2030 reaching an estimated $75 bn within the next decade. This article focusses on the recent and anticipated future uptake of biosimilars as well as the diverse rates of uptake that are expected across different geographies and molecules. In addition, the major drivers of this anticipated growth are briefly explored.
Recent biosimilar launches demonstrate a diverse range of uptake depending on the molecule and the geography in which they were launched. Globally, the uptake of biosimilar insulins for diabetes such as insulin glargine and insulin lispro has been slow while the uptake of biosimilars for oncology indications such as bevacizumab, rituximab and trastuzumab has been much more rapid. On average, the uptake of molecules for other indications such as adalimumab, infliximab and teriparatide fall in between these groups.
At a country level, there are exceptions to these general observations that can be partially explained by acceptance among prescribers and patients, the strength of policies which encourage their use, price differentials, and whether the country employs a single- or multi-winner tender system. In the case of insulins, there is reluctance among prescribers and patients to use biosimilars due to concerns about safety and disease control1,2 while in Europe for example, the European Medicines Agency (EMA) has left decisions about interchangeability and substitution to individual countries.3 Responding to the high cost of biologics for oncology indications, several countries have adopted policies which are increasing the use of biosimilars. For example, in Spain and Poland, biosimilars must be priced at least 25% and 40% below the originator, respectively, and in Norway, oncology biosimilars have secured most hospital contracts thereby driving biosimilar uptake.4
A key driver of biosimilar volume growth over the next decade is the expected number of loss of protection (LoP) events for originator brands. The dates of LoP assumptions in Forecast Link are based not only on key process patent expiries, but also any evidence of biosimilar development in the pipeline. Between 2021 and 2030, these LoP events are likely to impact brands which collectively accounted for global sales of approximately $144 bn in 2020.
IQVIA’s Forecast Link has analyzed the historical uptake of biosimilars at a country level and projected this uptake into the future based on historical trends and the expectations of experts. If appropriate, these assumptions are based on the three groups mentioned above, i.e. oncology, insulin and other molecules. Where historic analogues are not available for a given country, regional averages are employed. These assumptions are then applied to future LoP events where the new biosimilar takes volume share from the originator biologic. Examples of recently adjusted assumptions based on Q2 2021 data are presented in the charts below.
At a regional level, Europe and North America will continue to account for the largest share of global biosimilar volume, although greater rates of volume growth are expected in the major Asian markets, Latin America and South East Asia and Australasia over the next decade.
Although there is much variation in biosimilar uptake based on molecule and geography, there is a high degree of certainty that biosimilar market share will grow significantly over the next decade. A high number of LoP events and more aggressive measures to reduce healthcare expenditure will drive the growth of biosimilars in the foreseeable future.
1 Chaplin, S. Biosimilar Insulins: will switching soon be the norm? Practical Diabetes 2021: 38 (4); 17-20. https://doi.org/10.1002/pdi.2346
2 White J, Wagner A, Patel H. The impact of biosimilar insulins on the diabetes landscape. J Manag Care Spec Pharm. 2021 Nov 2:1-8. doi: 10.18553/jmcp.2021.21253. Epub ahead of print. PMID: 34726499.
3 Why the Reluctance to Use Biosimilar Insulins for Diabetes? https://www.medscape.com/viewarticle/906499#vp_1 (accessed Dec 2021)
4 IQVIA Market Prognosis (2021-2025) Country Reports
IQVIA Forecast Link provides regularly updated and fully segmentable sales and volume forecasts across 10,000 products, 600 diseases and 73 countries. Gain insights into current and future market landscapes and power your strategic decision making via this single easy-to-use platform providing unrivalled breadth of coverage. To learn more, please view the Forecast Link Video.